Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
NMPA Aims to Back Innovative Drugs First Launched in CN
Recommend 75 Positive 113 Negative 38 |
||||
|
||||
|
In order to encourage drugmakers to launch innovative drugs first in China, China intends to ramp up service support across the entire chain from communication and exchanges to clinical trials, registration applications, and review and approval for innovative drugs with new mechanisms and new targets, Chinese media reported, citing the initiatives outlined by Li Li, director of the National Medical Products Administration (NMPA), at the National Drug Regulation Work Conference held on January 6. Li also stressed that the NMPA will implement targeted measures and advance several key tasks in 2026, including the implementation of a drug trial data protection system and a study on the establishment of market exclusivity periods for pediatric drugs and medicines for rare diseases. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
